The latest price target for ProQR Therapeutics (NASDAQ:PRQR) was reported by HC Wainwright & Co. on May 10, 2024. The analyst firm set a price target for $5.00 expecting PRQR to rise to within 12 months (a possible 180.90% upside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for ProQR Therapeutics (NASDAQ:PRQR) was provided by HC Wainwright & Co., and ProQR Therapeutics reiterated their buy rating.

The last upgrade for ProQR Therapeutics NV happened on November 8, 2023 when Chardan Capital raised their price target to $2. Chardan Capital previously had a neutral for ProQR Therapeutics NV.

The last downgrade for ProQR Therapeutics NV happened on August 12, 2022 when Chardan Capital changed their price target from N/A to N/A for ProQR Therapeutics NV.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ProQR Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ProQR Therapeutics was filed on May 10, 2024 so you should expect the next rating to be made available sometime around May 10, 2025.

While ratings are subjective and will change, the latest ProQR Therapeutics (PRQR) rating was a reiterated with a price target of $5.00 to $5.00. The current price ProQR Therapeutics (PRQR) is trading at is $1.78, which is out of the analyst’s predicted range.